Rheumatic Diseases in Reproductive Age—the Possibilities and the Risks
Bogna Grygiel‐Górniak, Elena Masiero, Briana Candace Nevaneeth et al. · Reproductive Sciences · 2022
Cited by 18 works. doi:10.1007/s43032-022-00901-6
Authors
References
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
- The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
- EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases
- Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
- Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection
- Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
- Birth outcomes in women who have taken leflunomide during pregnancy
- Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus
- Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study